GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gemina Laboratories Ltd (XCNQ:GLAB) » Definitions » Net Income From Continuing Operations

Gemina Laboratories (XCNQ:GLAB) Net Income From Continuing Operations : C$-4.33 Mil (TTM As of Apr. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Gemina Laboratories Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Gemina Laboratories's net income from continuing operations for the three months ended in Apr. 2024 was C$-0.83 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Apr. 2024 was C$-4.33 Mil.

Gemina Laboratories Net Income From Continuing Operations Historical Data

The historical data trend for Gemina Laboratories's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gemina Laboratories Net Income From Continuing Operations Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24
Net Income From Continuing Operations
- -4.74 -5.98 -5.22

Gemina Laboratories Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.71 -1.58 -1.17 -0.76 -0.83

Gemina Laboratories Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Apr. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gemina Laboratories Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gemina Laboratories Ltd (XCNQ:GLAB) » Definitions » Net Income From Continuing Operations
Comparable Companies
TSX:ATE TSXV:GSD TSX:MBX TSX:TH TSXV:TTI XCNQ:ACOG TSXV:MSCL TSXV:COV TSX:APS TSXV:CZO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
GLABF:USA
Address
3800 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Website
https://www.geminalabs.com
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.
Executives
James Damian Tansey Director

Gemina Laboratories Headlines

No Headlines